FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297309719> ?p ?o ?g. }

• W4297309719 endingPage "1515" @default.
• W4297309719 startingPage "1509" @default.
• W4297309719 abstract "The present study examined whether rofecoxib (VIOXX®), a new specific inhibitor of cyclooxygenase-2 (COX-2), would interfere with the desired antiplatelet effects of aspirin. Thus, the effects of rofecoxib on inhibition of ex vivo serumgenerated thromboxane B2 (TXB2) and platelet aggregation by low doses (81 mg) of aspirin were examined in healthy volunteers. This was a double-blind, randomized, placebo-controlled, parallel study of two treatment groups (n = 12 per group) in which subjects received 50 mg of rofecoxib or placebo for 10 days in a blinded fashion. Subjects also received 81 mg aspirin once on each of days 4 through 10 in an open-label fashion. Blood for measurement of serum TXB2 production and platelet aggregation studies was collected on day 1 (prior to rofecoxib/placebo), on day 4 (prior to aspirin), and on day 10 (before and 4 hours following the seventh dose of aspirin). Platelet-derived serum TXB2 (COX-1 assay) was measured in blood clotted for 1 hour at 37°C. Platelet aggregation was independently induced employing 1 mM arachidonic acid and 1 μg/mL collagen as agonists. Rofecoxib administered alone had no significant effect on serum TXB2 production or platelet aggregation (day 4). TXB2 production was inhibited 98.4% by aspirin coadministered with either rofecoxib or placebo (day 10). Similarly, platelet aggregation induced by arachidonic acid was inhibited 93.7% and 93.5% by aspirin coadministered with either rofecoxib or placebo, respectively (day 10). The comparable values for inhibition of collagen-induced platelet aggregation were 86.8% and 90.8%, respectively. No important clinical or laboratory adverse experiences were observed. In conclusion, rofecoxib alone (50 mg QD for 4 days) did not inhibit serum TXB2 production or platelet aggregation. In addition, rofecoxib (50 mg QD for 10 days) did not alter the antiplatelet effects of low-dose aspirin (inhibition of platelet aggregation and TXB2 production). Rofecoxib was generally well tolerated when administered alone or in combination with low-dose aspirin." @default.
• W4297309719 created "2022-09-28" @default.
• W4297309719 creator A5026975469 @default.
• W4297309719 creator A5031932051 @default.
• W4297309719 creator A5052512888 @default.
• W4297309719 creator A5056261176 @default.
• W4297309719 creator A5062664304 @default.
• W4297309719 creator A5068447666 @default.
• W4297309719 creator A5076373959 @default.
• W4297309719 creator A5079298473 @default.
• W4297309719 creator A5089213629 @default.
• W4297309719 date "2000-12-01" @default.
• W4297309719 modified "2023-10-14" @default.
• W4297309719 title "A New Cyclooxygenase‐2 Inhibitor, Rofecoxib (VIOXX®), Did Not Alter the Antiplatelet Effects of Low‐Dose Aspirin in Healthy Volunteers" @default.
• W4297309719 cites W1529632581 @default.
• W4297309719 cites W1536681507 @default.
• W4297309719 cites W1575557511 @default.
• W4297309719 cites W1587059515 @default.
• W4297309719 cites W1587123510 @default.
• W4297309719 cites W1648593433 @default.
• W4297309719 cites W1974026314 @default.
• W4297309719 cites W1981662925 @default.
• W4297309719 cites W1997364548 @default.
• W4297309719 cites W2000759877 @default.
• W4297309719 cites W2002895224 @default.
• W4297309719 cites W2003599597 @default.
• W4297309719 cites W2009962040 @default.
• W4297309719 cites W2012810767 @default.
• W4297309719 cites W2014034874 @default.
• W4297309719 cites W2039358393 @default.
• W4297309719 cites W2051086902 @default.
• W4297309719 cites W2056420697 @default.
• W4297309719 cites W2089923844 @default.
• W4297309719 cites W2094584843 @default.
• W4297309719 cites W2125389594 @default.
• W4297309719 cites W2340194019 @default.
• W4297309719 cites W2419483426 @default.
• W4297309719 doi "https://doi.org/10.1177/009127000004001224" @default.
• W4297309719 hasPublicationYear "2000" @default.
• W4297309719 type Work @default.
• W4297309719 citedByCount "17" @default.
• W4297309719 countsByYear W42973097192012 @default.
• W4297309719 countsByYear W42973097192017 @default.
• W4297309719 countsByYear W42973097192022 @default.
• W4297309719 countsByYear W42973097192023 @default.
• W4297309719 crossrefType "journal-article" @default.
• W4297309719 hasAuthorship W4297309719A5026975469 @default.
• W4297309719 hasAuthorship W4297309719A5031932051 @default.
• W4297309719 hasAuthorship W4297309719A5052512888 @default.
• W4297309719 hasAuthorship W4297309719A5056261176 @default.
• W4297309719 hasAuthorship W4297309719A5062664304 @default.
• W4297309719 hasAuthorship W4297309719A5068447666 @default.
• W4297309719 hasAuthorship W4297309719A5076373959 @default.
• W4297309719 hasAuthorship W4297309719A5079298473 @default.
• W4297309719 hasAuthorship W4297309719A5089213629 @default.
• W4297309719 hasConcept C126322002 @default.
• W4297309719 hasConcept C142724271 @default.
• W4297309719 hasConcept C181199279 @default.
• W4297309719 hasConcept C185592680 @default.
• W4297309719 hasConcept C204787440 @default.
• W4297309719 hasConcept C27081682 @default.
• W4297309719 hasConcept C2776785769 @default.
• W4297309719 hasConcept C2777628954 @default.
• W4297309719 hasConcept C2778582115 @default.
• W4297309719 hasConcept C2779216453 @default.
• W4297309719 hasConcept C2779689624 @default.
• W4297309719 hasConcept C2781080829 @default.
• W4297309719 hasConcept C2993802102 @default.
• W4297309719 hasConcept C42219234 @default.
• W4297309719 hasConcept C55493867 @default.
• W4297309719 hasConcept C71924100 @default.
• W4297309719 hasConcept C89560881 @default.
• W4297309719 hasConcept C98274493 @default.
• W4297309719 hasConceptScore W4297309719C126322002 @default.
• W4297309719 hasConceptScore W4297309719C142724271 @default.
• W4297309719 hasConceptScore W4297309719C181199279 @default.
• W4297309719 hasConceptScore W4297309719C185592680 @default.
• W4297309719 hasConceptScore W4297309719C204787440 @default.
• W4297309719 hasConceptScore W4297309719C27081682 @default.
• W4297309719 hasConceptScore W4297309719C2776785769 @default.
• W4297309719 hasConceptScore W4297309719C2777628954 @default.
• W4297309719 hasConceptScore W4297309719C2778582115 @default.
• W4297309719 hasConceptScore W4297309719C2779216453 @default.
• W4297309719 hasConceptScore W4297309719C2779689624 @default.
• W4297309719 hasConceptScore W4297309719C2781080829 @default.
• W4297309719 hasConceptScore W4297309719C2993802102 @default.
• W4297309719 hasConceptScore W4297309719C42219234 @default.
• W4297309719 hasConceptScore W4297309719C55493867 @default.
• W4297309719 hasConceptScore W4297309719C71924100 @default.
• W4297309719 hasConceptScore W4297309719C89560881 @default.
• W4297309719 hasConceptScore W4297309719C98274493 @default.
• W4297309719 hasIssue "12" @default.
• W4297309719 hasLocation W42973097191 @default.
• W4297309719 hasOpenAccess W4297309719 @default.
• W4297309719 hasPrimaryLocation W42973097191 @default.
• W4297309719 hasRelatedWork W1965103142 @default.
• W4297309719 hasRelatedWork W1971038196 @default.
• W4297309719 hasRelatedWork W1995723625 @default.

• next